AbbVie (ABBV) and Neurocrine (NBIX) Announce Positive Pivotal Phase 3 Data for Elagolix in Premenopausal Women
Go back to AbbVie (ABBV) and Neurocrine (NBIX) Announce Positive Pivotal Phase 3 Data for Elagolix in Premenopausal Women| AbbVie (NYSE: ABBV) | Delayed: 167.29 -0.51 (0.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $167.80 | 52 Week High | $68.12 | |||
| Open | $167.66 | 52 Week Low | $50.71 | |||
| Day High | $169.29 | P/E | 36.29 | |||
| Day Low | $165.57 | EPS | $4.61 | |||
| Volume | 5,502,726 | |||||
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 137.76 -1.21 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $138.97 | 52 Week High | $58.46 | |||
| Open | $139.37 | 52 Week Low | $31.25 | |||
| Day High | $139.37 | P/E | N/A | |||
| Day Low | $136.06 | EPS | $-0.69 | |||
| Volume | 735,781 | |||||
